Table 4.
Kaplan-Meier estimates for relapse following a rise in PR3-ANCA*.
| ALBIA | |||||
|---|---|---|---|---|---|
| Median months to relapse | Cumulative Relapse, % (95% C.I.) | ||||
| N* | 6-months | 12 months | 18 months | ||
| Overall | |||||
| Any relapse | 72 | 15.4 | 26 (15, 35) | 42 (29, 52) | 52 (38, 62) |
| Severe relapse | 80 | 22.1 | 22 (12, 30) | 35 (23, 45) | 42 (30, 52) |
| Baseline capillaritis | |||||
| Any relapse | 58 | 22.1 | 23 (11, 33) | 36 (22, 48) | 44 (29, 56) |
| Severe relapse | 66 | 24.2 | 19 (8, 28) | 32 (19, 42) | 37 (24, 48) |
| Baseline renal | |||||
| Any relapse | 44 | – | 26 (11, 38) | 31 (15, 44) | 39 (22, 53) |
| Severe relapse | 51 | 37.0 | 20 (8, 31) | 29 (15, 41) | 36 (20, 52) |
| Baseline DAH | |||||
| Any relapse | 20 | 10.2 | 43 (15, 61) | 54 (24, 72) | 67 (35, 83) |
| Severe relapse | 22 | 14.3 | 34 (10, 51) | 49 (22, 67) | 60 (31, 77) |
| Rituximab group | |||||
| Any relapse | 37 | 14.6 | 22 (7, 35) | 42 (24, 57) | 55 (34, 69) |
| Severe relapse | 44 | 21.7 | 21 (8, 32) | 35 (19, 48) | 45 (28, 59) |
| Cyclophosphamide | |||||
| Any relapse | 35 | 18.2 | 29 (12, 42) | 41 (22, 56) | 48 (28, 63) |
| Severe relapse | 36 | 24.2 | 22 (7, 35) | 34 (16, 48) | 38 (19, 52) |
*
Analyses include individuals who experienced a rise in PR3-ANCA during follow-up while at risk for the given relapse endpoint. Individuals who experienced an ANCA increase concurrent with the given relapse event are not included. Time zero corresponds to the date of the ANCA increase.